ZALTRAP

ਉਤਪਾਦ ਝਲਕ

About ZALTRAP

ZALTRAP is a prescription medicine used in combination with specific chemotherapy regimens for the treatment of patients with metastatic colorectal cancer. This medication is administered by a healthcare professional through an intravenous infusion. It is designed to be used in patients whose disease has progressed despite prior treatment with an oxaliplatin-containing regimen. ZALTRAP is classified as a vascular endothelial growth factor inhibitor, which functions by interfering with the development of new blood vessels that tumors require for growth and survival.

Key Benefits & Uses

• Used in combination with FOLFIRI chemotherapy for metastatic colorectal cancer.
• Targets the biological pathways that support tumor blood supply.
• Provides a therapeutic option for patients who have experienced disease progression after initial treatments.

Active Ingredient & Action

The active ingredient in ZALTRAP is aflibercept. This protein acts as a soluble receptor that binds to vascular endothelial growth factor-A and placental growth factor. By sequestering these proteins, the medication prevents them from binding to their native receptors, thereby inhibiting the formation of new blood vessels within the tumor environment.

Important Notes

ZALTRAP must be administered under the supervision of a qualified oncologist. Patients should discuss their full medical history and current medications with their healthcare provider before beginning treatment. Regular monitoring is required throughout the course of therapy to manage potential complications and assess clinical response.